Abstract:Abstract. – OBJECTIVE: SOX2 (Sry-related high-mobility box SOX-2) is a transcription factor, which is essential for maintaining the cancer cell stemness. However, the role of microRNAs targeting SOX2 in cancer cell stemness remains unclear. We examined the effect of miR-590-5p, which targeted SOX2, on the breast cancer cell stemness and metastasis. MATERIALS AND METHODS: We predicted and screened microRNA targeting SOX2, and further investigated the regulatory role of miR-590-5p on the level of SOX2 with Western blot, luciferase reporting assay and qRT-PCR analysis. Flow cytometry was performed to detect the effect of miR-590-5p on the breast cancer stem cell population with ALDEFLUOR Assay. We inoculated the breast cancer cells transfected with or without miR-590-5p to NOD/SCID mice to detect the tumorigenicity in vivo. Finally, forty-nine pairs of breast cancer samples and adjacent noncancerous tissues were obtained, and immunohistochemistry (IHC) with SOX2 antibody and qRT-PCR assay were used to quantify the expression of miR-590-5p in breast cancer samples. RESULTS: miR-590-5p significantly downregulated the SOX2 protein expression, and inhibition of miR-590-5p increased SOX2 expression. The luciferase reporter assay indicated that miR-5905p decreased the SOX2 3’UTR (3’ untranslated region) reporter activity but not the luciferase activity of the mutant reporter, in which the binding sites for miR-590-5p were mutated. ALDEFLUOR Assay showed that miR-590-5p significantly decreased breast cancer stem cells population. NOD/SCID nude mice experiments indicated that miR-590-5p significantly inhibited tumorigenicity of breast cancer cells. IHC assay and qRTPCR suggested that miR-590-5p expression was downregulated in breast cancer patients, and negatively correlated with SOX2. CONCLUSIONS: miR-590-5p inhibited breast cancer cell stemness through targeting SOX2. Our study indicated that miR-590-5p might be a useful strategy for breast cancer treatment.

miRNA‐215‐5p suppresses the aggressiveness of breast cancer cells by targeting Sox9

<i>MiRNA-145-5p</i> Restrains Malignant Behaviors of Breast Cancer Cells Via Downregulating<i> H2AFX</i> Expression

MiR-133b targets Sox9 to control pathogenesis and metastasis of breast cancer

MicroRNA miR-5905 p inhibits breast cancer cell stemness and metastasis by targeting SOX 2

MicroRNA Mir-590-5p Inhibits Breast Cancer Cell Stemness and Metastasis by Targeting SOX2.

miR-155-5p Promotes Invasion and Migration of MCF-7 Breast Cancer Cell by Down-regulating SOX1

Tumor Suppressive Microrna-193B Promotes Breast Cancer Progression Via Targeting DNAJC13 and RAB22A.

Microrna-181B Suppresses the Metastasis of Lung Cancer Cells by Targeting Sex Determining Region Y-related High Mobility Group-Box 6 (Sox6)

Microrna-499A Promotes the Progression and Chemoresistance of Cervical Cancer Cells by Targeting SOX6

MicroRNA-99a Inhibits Tumor Aggressive Phenotypes Through Regulating HOXA1 in Breast Cancer Cells.

Mir‑139‑3p Suppresses the Invasion and Migration Properties of Breast Cancer Cells by Targeting RAB1A

Suppression of cell growth and invasion by miR-205 in breast cancer

Mir-24-3p Promotes Cell Migration and Proliferation in Lung Cancer by Targeting SOX7.

miR-144 functions as a tumor suppressor in breast cancer through inhibiting ZEB1/2-mediated epithelial mesenchymal transition process.

Hsa-miR-206 Represses the Proliferation and Invasion of Breast Cancer Cells by Targeting Cx43.

Microrna-497-5p Targeted Sox9 To Inhibit Proliferation, Migration And Invasion Of Glioma Cells

Mir-497-5p Inhibits Tumor Cell Growth and Invasion by Targeting SOX5 in Non-Small-cell Lung Cancer

MiR-9 promotes G-MDSC recruitment and tumor proliferation by targeting SOCS3 in breast cancer

MicroRNA-101 Inhibits Growth, Proliferation and Migration and Induces Apoptosis of Breast Cancer Cells by Targeting Sex-Determining Region Y-Box 2

MicroRNA-34a Suppresses Breast Cancer Cell Proliferation and Invasion by Targeting Notch1

MicroRNA-409-5p is Upregulated in Breast Cancer and Its Downregulation Inhibits Cancer Development Through Downstream Target of RSU1